OverviewSuggest Edit

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales). The Group has more than 4,500 employees.
HQBoulogne-Billancourt, FR
Employee Ratings4
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2021)5,700
Share Price (Nov 2021)€86.4(+2%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ipsen

Aymeric le Chatelier

Aymeric le Chatelier

Marc de Garidel

Marc de Garidel

Richard Paulson

Richard Paulson

Chief Executive Officer - Ipsen North America
David Loew

David Loew

Chief Executive Officer
Shahrzad Amirani

Shahrzad Amirani

Vice President, Head of New Products & Innovation
Brad Carter

Brad Carter

Sr. Director, Finance & Supply Chain
Show more

Ipsen Office Locations

Ipsen has offices in Boulogne-Billancourt, Glen Waverley, Merelbeke and Hoofddorp
Boulogne-Billancourt, FR (HQ)
65 Quai Georges Gorse
Glen Waverley, AU
540 Springvale Rd
Merelbeke, BE
Guldensporenpark 87
Hoofddorp, NL
Taurusavenue 33b
Show all (4)

Ipsen Financials and Metrics

Ipsen Revenue

Market capitalization (10-Nov-2021)


Closing stock price (10-Nov-2021)

Ipsen's current market capitalization is €7.2 b.
Show all financial metrics

Ipsen Acquisitions / Subsidiaries

Company NameDateDeal Size
Clementia PharmaceuticalsFebruary 25, 2019$1.31 b

Ipsen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Ipsen Online and Social Media Presence

Embed Graph

Ipsen Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

Ipsen News and Updates

Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns

Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns

Verisk Elects Laura K. Ipsen to Board of Directors

JERSEY CITY, N.J., November 19, 2019 — Verisk (Nasdaq:VRSK), a leading data analytics provider, announces the addition of Laura K. Ipsen to its board of directors, effective January 1. read more

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP --read more

Clayton, Dubilier & Rice erweitert europäisches Gesundheitswesen-Team mit der Ernennung von Jean-Luc Belingard, ehemaliger CEO von bioMérieux, Ipsen und Roche Diagnostics zum operativen Berater seiner Fonds

NEW YORK und LONDON, 14. Oktober 2019 /PRNewswire/ -- Clayton, Dubilier & Rice („CD&R") gab heute die Ernennung von Jean-Luc Belingard, einer Führungskraft mit einer erfolgreichen Karriere bei weltweiten Pharmaunternehmen, zum Operating Advisor für CD&R Funds bekannt. Herr Belingard wird…

Clayton, Dubilier & Rice Expands European Healthcare Team with Appointment of Jean-Luc Belingard, former CEO of bioMérieux, Ipsen, and Roche Diagnostics, as an Operating Advisor to its Funds

NEW YORK and LONDON, Oct. 14, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice ("CD&R") today announced the appointment of Jean-Luc Belingard, a senior executive with a successful career leading global pharmaceutical businesses, as an Operating Advisor to CD&R Funds. Mr. Belingard will work…

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada B…
Show more

Ipsen Blogs

FY2019 and beyond: paving the way for our next phase of growth.

Today, Ipsen announced its FY2019 results, and I would like to take a moment to reflect on another strong year and how we are paving the way for our next phase of growth.  In 2019, we reported Group net sales which exceeded €2.5 billion for the first time, representing a 14.8% growth in sales. I […]…

Ipsen – Full Year 2019 Results Conference Call – February 13, 2020 at 2:30pm CET / 8:30 EST

Date:            Thursday, February 13, 2020 Time:            Conference call and webcast – 2:30pm CET / 8:30 EST   Participants should dial in to the call approximately 5 to 10 minutes prior to its start. Standard International: +44 (0) 2071-928-000 France and continental Europe: + 33 (0) 1 76 70 0…

Ipsen in Neuroscience: A new decade of technological possibilities for Neuroscience at Ipsen

John Chaddock, VP Interim Global Head Neuroscience Therapeutic Area, Site Head Ipsen Bioinnovation, Ipsen As we welcome a new decade, it seems timely to reflect on the progress Ipsen has made in neuroscience and to reaffirm our commitment to continued innovation. For over 30 years, Ipsen has been a …

From collaboration to evaluation: developing a new way to evaluate patient wellbeing in NETs

Working with patients, for patients, underlines everything we do at Ipsen. Understanding their quality of life is a way we can measure the impact of our therapies. However, we need to be able to collect this information in an accurate and targeted way to ensure we can use it to improve our treatment…

Demerger of Mayroy SA and Internal reclassification of Ipsen shares

Luxembourg (France), 19 December 2019 – As previously announced in a press release dated November 5th, 2019Mayroy SA’s shareholders, (the Beaufour and Schwabe families), have now implemented the demerger of Mayroy SA (Ipsen’s controlling holding company) This demerger was completed on December 19th,…

On World Anti-Corruption Day, Ipsen re-affirms its commitment to the principles of the United Nations Global Compact Program

  Understanding the importance of conducting business with the highest ethical standards, we asked Dominique Laymand, EVP, Ethics and Social Responsibility Chief Officer, three important questions to mark World Anti-Corruption Day:   Dominique, why is anti-corruption so important in today’s world? F…
Show more

Ipsen Frequently Asked Questions

  • When was Ipsen founded?

    Ipsen was founded in 1929.

  • Who are Ipsen key executives?

    Ipsen's key executives are Aymeric le Chatelier, Marc de Garidel and Richard Paulson.

  • How many employees does Ipsen have?

    Ipsen has 5,700 employees.

  • Who are Ipsen competitors?

    Competitors of Ipsen include Zentiva, Idorsia and EMS Pharma.

  • Where is Ipsen headquarters?

    Ipsen headquarters is located at 65 Quai Georges Gorse, Boulogne-Billancourt.

  • Where are Ipsen offices?

    Ipsen has offices in Boulogne-Billancourt, Glen Waverley, Merelbeke and Hoofddorp.

  • How many offices does Ipsen have?

    Ipsen has 4 offices.